Search results for "safe"

showing 10 items of 2099 documents

Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: a comprehensive review of literature

2016

BACKGROUND Everolimus, an oral mTOR (mammalian target of rapamycin) inhibitor, is currently approved for the treatment of progressive pancreatic neuroendocrine tumors (NETs). Although promising, only scattered data, often from nondedicated studies, are available for extrapancreatic NETs. PATIENTS AND METHODS A systematic review of the published data was performed concerning the use of everolimus in extrapancreatic NET, with the aim of summarizing the current knowledge on its efficacy and tolerability. Moreover, the usefulness of everolimus was evaluated according to the different sites of the primary. RESULTS The present study included 22 different publications, including 874 patients and 4…

0301 basic medicineOncologyCancer ResearchLung NeoplasmsAdrenal Gland NeoplasmsColorectal NeoplasmNeuroendocrine tumorsSettore MED/13 - EndocrinologiaAntineoplastic Agent0302 clinical medicineEndocrinologyNeuroendocrine tumors; everolimus; extrapancreatic; efficacy; safetyProspective cohort studyNeuroendocrine TumorsEverolimuOncologyTolerability030220 oncology & carcinogenesisIleal NeoplasmSafetyColorectal Neoplasmsmedicine.drugHumanmedicine.medical_specialtyEfficacyAntineoplastic AgentsPheochromocytomaExtrapancreatic neuroendocrine tumorDisease-Free Survival03 medical and health sciencesNeuroendocrine tumorStomach NeoplasmsStomach NeoplasmInternal medicinemedicineHumansEverolimusThyroid NeoplasmsAdverse effectEverolimusbusiness.industryRetrospective cohort studymedicine.diseaseDiscontinuationCarcinoma NeuroendocrineClinical trialIleal NeoplasmsAdrenal Gland NeoplasmLung Neoplasm030104 developmental biologyEndocrinologybusiness
researchProduct

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis

2018

Background: At present, there is uncertainty on the best systemic treatment in first-line setting for RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients. Indeed, several chemotherapy and biologics combinations showed an improvement on survival. We performed a systematic review with a pair-wise and bayesan meta-analysis to rank the best strategy for these patients. Methods: A systematic literature search through March 2017 was performed to evaluate the association between several treatment combinations and overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicity rate (TR) in RAS WT mCRC patients. Data were extracted from studies and pooled…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentBayesian probabilitySidednessDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIn patientMeta-analysiSystemic chemotherapyNeoplasm MetastasisRAS wild-typeChemotherapyVbusiness.industryMetastatic colorectal cancerWild typeBayes TheoremHematologymedicine.diseaseNeoadjuvant TherapyFirst line treatmentMeta-analysisSafety profileGenes ras030104 developmental biologyOncology030220 oncology & carcinogenesisMeta-analysisSystemic chemotherapy.Colorectal Neoplasmsbusiness
researchProduct

Is Danggui Safe to be Taken by Breast Cancer Patients?-A Skepticism Finally Answered by Comprehensive Preclinical Evidence.

2019

Angelica sinensis (AS, Danggui) has long been regarded to stimulate breast cancer growth; hence, the use of AS in breast cancer patients remains a major concern for both patients and practitioners. Since safety studies of herbs would be unethical to carry out in patients, the present study aimed to investigate the potential unsafe effects of AS in a systematic pre-clinical approach. Human breast cancer cells, breast orthotopic tumor-bearing mouse models, as well as primary breast cancer cells from patients’ tumors were used to evaluate the effect of AS hot water extract on the progression of breast tumors and/or growth of breast cancer cells. We showed that AS is not that stimulatory in bre…

0301 basic medicineOncologysafetymedicine.medical_specialtyprimary breast cancer cellsmedicine.drug_classXenotransplantationmedicine.medical_treatmentTraditional Chinese medicine03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicinemedicinePharmacology (medical)skin and connective tissue diseasesOriginal ResearchPharmacologySafety studiesbusiness.industrylcsh:RM1-950Angelica sinensisChinese herbal medicinesmedicine.diseaselcsh:Therapeutics. Pharmacology030104 developmental biologyEstrogen030220 oncology & carcinogenesisCancer cellestrogenic herbsBreast cancer cellsPrimary breast cancerbusinessFrontiers in pharmacology
researchProduct

Multi-criteria framework as an innovative tradeoff approach to determine the shelf-life of high pressure-treated poultry

2016

International audience; A multi-criteria framework combining safety, hygiene and sensorial quality was developed to investigate the possibility of extending the shelf-life and/or removing lactate by applying High Hydrostatic Pressure (HHP) in a ready-to-cook (RTC) poultry product. For this purpose, Salmonella and Listeria monocytogenes were considered as safety indicators and Escherichia coli as hygienic indicator. Predictive modeling was used to determine the influence of HHP and lactate concentration on microbial growth and survival of these indicators. To that end, probabilistic assessment exposure models developed in a previous study (Lerasle, M., Guillou, S., Simonin, H., Anthoine, V.,…

0301 basic medicineOrganolepticHydrostatic pressureSodium lactateEscherichia-coliPoultrylLsteria-monocytogenesInactivationchemistry.chemical_compoundSalmonella[SDV.IDA]Life Sciences [q-bio]/Food engineeringFood scienceCookingPoultry ProductsPotassium lactateMathematics2. Zero hungerHigh hydrostatic-pressurePoultry product[ SDV.IDA ] Life Sciences [q-bio]/Food engineeringRisk-risk trade-off;Lactate;Food hygiene;Food safety;Sensorial qualitySensorial qualityRisk-risk trade-off04 agricultural and veterinary sciencesGeneral Medicine040401 food scienceMeat ProductsCured beef carpaccioTasteIn-ground beefMeat-products030106 microbiologyShelf lifeMicrobiologyFood safety03 medical and health sciences0404 agricultural biotechnologyChicken meatFood PreservationEscherichia coliHydrostatic PressureFood hygieneFood microbiologyAnimalsHumansExposure assessmentbusiness.industryDifferent temperaturesFood safetyListeria monocytogeneschemistryFood StorageConsumer Product SafetyLactatebusinessFood Science
researchProduct

The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency

2017

International audience; A good understanding of the natural history of rare genetic lipid disorders is a pre-requisite for successful patient management. Disease registries have been helpful in this regard. Lipoprotein Lipase Deficiency (LPLD) is a rare, autosomal-recessive lipid disorder characterized by severe hypertriglyceridemia and a very high risk for recurrent acute pancreatitis, however, only limited data are available on its natural course. Alipogene tiparvovec (Glybera (R)) is the first gene therapy to receive Marketing Authorization in the European Union; GENIALL (GENetherapy In the MAnagement of Lipoprotein Lipase Deficiency), a 15-year registry focusing on LPLD was launched in …

0301 basic medicinePediatricsPathologySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]Familial hypercholesterolemiaDisease030204 cardiovascular system & hematologyGeneTHERAPY0302 clinical medicineFamilialRisk FactorsHyperchylomicronemiaAlipogene tiparvovecRegistriesFAMILIAL HYPERCHOLESTEROLEMIAmedia_commonHypertriglyceridemiaPrognosis3. Good healthNatural historySystematic reviewPhenotypeDISEASESSAFETYHyperlipoproteinemia Type ICardiology and Cardiovascular Medicinemedicine.medical_specialtyAPHERESISRegistryFamilial chylomicronemia syndromeGENIALLLysosomal acid lipase deficiencyLipid Metabolism Inborn Errors03 medical and health sciencesLipoprotein lipase deficiencyRare DiseasesGene therapychylomicronemia syndromemedicinemedia_common.cataloged_instanceHumansGenetic Predisposition to DiseaseEuropean unionLipoprotein lipase deficiency (LPLD)business.industryALIPOGENE TIPARVOVEC AAV1-LPLS447Xmedicine.diseaseAlipogene tiparvovecLipoprotein Lipase030104 developmental biologyOrphan diseasebusiness
researchProduct

Statistical characterization of deviations from planned flight trajectories in air traffic management

2016

Understanding the relation between planned and realized flight trajectories and the determinants of flight deviations is of great importance in air traffic management. In this paper we perform an in depth investigation of the statistical properties of planned and realized air traffic on the German airspace during a 28 day periods, corresponding to an AIRAC cycle. We find that realized trajectories are on average shorter than planned ones and this effect is stronger during night-time than daytime. Flights are more frequently deviated close to the departure airport and at a relatively large angle to destination. Moreover, the probability of a deviation is higher in low traffic phases. All the…

0301 basic medicinePhysics - Physics and SocietyEngineeringStrategy and ManagementFOS: Physical sciencesTransportationPhysics and Society (physics.soc-ph)Management Monitoring Policy and LawStability (probability)socio-technical complex systemAviation safety03 medical and health sciencesControl theory0502 economics and business11. SustainabilityAir traffic management complex networks trajectoriesSimulationRandomness050210 logistics & transportationbusiness.industry05 social sciencesAir traffic managementAir traffic controlSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)030104 developmental biologyMetric (mathematics)TrajectoryNull hypothesisbusinessLawair traffc managementJournal of Air Transport Management
researchProduct

How to deal with context? A context-mapping tool for quality and safety in nursing homes and homecare (SAFE-LEAD Context)

2019

Abstract Objective The objective of this paper is to develop a context-mapping tool (SAFE-LEAD Context) adapted to the nursing home and homecare setting. These two contexts represent a substantial variability, but studies focusing on the types and roles of contextual factors in quality and safety in these care settings are lacking. Results We conducted a step-wise collaborative design process consisting of mapping of key contextual factors as perceived by managers in Norwegian nursing homes and homecare, then created a draft tool discussed in a consortium workshop with co-researchers, and ran an international cross-country comparison. The SAFE-LEAD Context tool is inspired by the Consolidat…

0301 basic medicineProcess managementQuality managementComputer scienceCross-country comparisonPsychological interventionlcsh:MedicineGeneral Biochemistry Genetics and Molecular BiologyHomecareCare setting03 medical and health sciencesPatient safety0302 clinical medicineHumans030212 general & internal medicineCollaborative designContext mappingQuality improvementCooperative BehaviorGrading (education)lcsh:Science (General)lcsh:QH301-705.5Quality of Health Care:Medical disciplines: 700 [VDP]pasientsikkerhetNursing homelcsh:RGeneral MedicineHome Care ServiceshjemmesykepleieNursing HomesResearch NotePatient safety030104 developmental biologysykehjemlcsh:Biology (General)VDP::Medisinske Fag: 700::Helsefag: 800::Sykepleievitenskap: 808Implementation researchNursing homeslcsh:Q1-390BMC Research Notes
researchProduct

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized…

2019

Objectives: Concomitant chemo-radiation is the standard treatment for unresectable stage III non-small cell lung cancer (LA-NSCLC), The aim of this study was to assess the safety and efficacy of oral vinorelbine and cisplatin (OVP) compared with etoposide and cisplatin (EP), both in combination with radiotherapy, in this setting. Material and methods: An open-label, randomized phase II trial was undertaken including 23 hospitals in Spain. Adults with untreated unresectable stage III NSCLC were randomizedl:1 to receive: oral vinorelbine (days 1 and 8 with cisplatin on day 1 in 3-week cycles; 2 cycles of induction, 2 cycles in concomitance) or etoposide (days 1-5 and 29-32 with cisplatin on d…

0301 basic medicinePulmonary and Respiratory MedicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsDisease-free survivalmedicine.medical_treatmentNeoplasm metastasisAdministration OralVinorelbine03 medical and health sciences0302 clinical medicineNon-small cell lung cancerInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansProgression-free survivalneoplasmsEtoposideAgedNeoplasm StagingEtoposideCisplatinbusiness.industryStandard treatmentVinorelbineChemoradiotherapyMiddle AgedPhase IIrespiratory tract diseasesRadiation therapySurvival RateClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisConcomitantFemalePatient SafetyCisplatinbusinessClinical trial Disease-free survival Etoposide Neoplasm metastasis Non-small cell lung cancer Phase II Vinorelbinemedicine.drug
researchProduct

MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC

2018

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industry03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyAtezolizumab030220 oncology & carcinogenesisInternal medicinemedicineErlotinibLong term safetybusinessmedicine.drugJournal of Thoracic Oncology
researchProduct

The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?

2017

The direct oral anticoagulants (DOACs) have been compared with parenteral anticoagulants and vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE) in several robust studies. DOACs have shown similar efficacy in preventing recurrent VTE and significant reductions in critical site (intracranial) bleeding, fatal bleeding, major and nonmajor bleeding. Warfarin and other VKAs are not dead as treatment modalities for VTE. A better way to describe the current situation is to use a boxing expression, “down but not out.” VKAs and parenteral anticoagulants still have a role to play in the management of VTE in several clinical settings. In indications where DOACs can be used, …

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyAdministration OralClinical settingsVitamin kCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineSecondary PreventionmedicineHumanscardiovascular diseasesIntensive care medicineOral anticoagulationCerebral Hemorrhagebusiness.industryWarfarinAnticoagulantsVenous ThromboembolismSafety profile030104 developmental biologyTreatment modalityvenous thromboembolism oral anticoagulation warfarin non-VKA oral anticoagulants safety efficacy030220 oncology & carcinogenesisWarfarinbusinessVenous thromboembolismmedicine.drug
researchProduct